Quantum BioPharma Ltd. Adjustments For Depreciation And Amortisation Expense
Quantum BioPharma Ltd. (QNTM) reported Adjustments For Depreciation And Amortisation Expense of $545.78 thousand for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-26.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense · last filed 2026-03-26
CAD
| Period end | Adjustments For Depreciation And Amortisation Expense 12 month |
|---|---|
| 2019-12-31 | 3.15M CAD 40-F/A · filed 2020-03-17 |
| 2018-12-31 | 183.19K CAD 40-F/A · filed 2020-03-17 |
USD
| Period end | Adjustments For Depreciation And Amortisation Expense 3 month | Adjustments For Depreciation And Amortisation Expense 6 month | Adjustments For Depreciation And Amortisation Expense 9 month | Adjustments For Depreciation And Amortisation Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $129.37K derived: 20-F 12 month − 6-K 9 month · filed 2026-03-26 | $274.71K derived: sum of 2 quarters · filed 2026-03-26 | $416.09K derived: sum of 3 quarters · filed 2026-03-26 | $545.78K 20-F · filed 2026-03-26 |
| 2025-09-30 | $145.34K derived: 6-K 9 month − 6-K 6 month · filed 2025-11-06 | $286.72K derived: sum of 2 quarters · filed 2025-11-06 | $416.41K 6-K · filed 2025-11-06 | $529.21K derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-06-30 | $141.38K derived: 6-K 6 month − 6-K/A 3 month · filed 2025-08-07 | $271.07K 6-K · filed 2025-08-07 | $383.88K derived: sum of 3 quarters · filed 2026-03-26 | $504.69K derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-03-31 | $129.69K 6-K/A · filed 2025-06-16 | $242.49K derived: sum of 2 quarters · filed 2026-03-26 | $363.31K derived: sum of 3 quarters · filed 2026-03-26 | $500.12K derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-12-31 | $112.80K derived: 20-F 12 month − 6-K 9 month · filed 2026-03-26 | $233.62K derived: sum of 2 quarters · filed 2026-03-26 | $370.43K derived: sum of 3 quarters · filed 2026-03-26 | $490.57K 20-F · filed 2026-03-26 |
| 2024-09-30 | $120.81K derived: 6-K 9 month − 6-K 6 month · filed 2025-11-06 | $257.63K derived: sum of 2 quarters · filed 2025-11-06 | $377.77K 6-K · filed 2025-11-06 | |
| 2024-06-30 | $136.81K derived: 6-K 6 month − 6-K/A 3 month · filed 2025-08-07 | $256.95K 6-K · filed 2025-08-07 | ||
| 2024-03-31 | $120.14K 6-K/A · filed 2025-06-16 | |||
| 2023-12-31 | $2.51M 20-F · filed 2026-03-26 | |||
| 2023-06-30 | $2.24M 6-K/A · filed 2024-08-19 | |||
| 2022-12-31 | $4.53M 20-F/A · filed 2025-03-31 | |||
| 2021-12-31 | $4.05M 20-F · filed 2024-04-02 | |||
| 2020-12-31 | $3.90M 20-F · filed 2023-03-31 | |||
| 2019-12-31 | $1.94M 40-F · filed 2021-03-17 |